News

INDUSTRY VETERAN BRINGS SALES EXPERTISE TO ALLOSOURCE

Monday, April 30, 2012

INDUSTRY VETERAN BRINGS SALES EXPERTISE TO ALLOSOURCE’S GROWING DISTRIBUTION NETWORK 

Colorado Spring Gazette: 'Tax on medical devices threatens profits, exec says'

Friday, April 27, 2012

A tax on medical devices approved in 2010 as part of federal health care reform legislation would wipe out all of the profits Colorado Springs-based Spectranetics Corp. expects to make this year when the tax takes effect next year, a top company executive said Friday.

The medical laser manufacturer expects to earn between $1.5 million and $3 million this year, which the company would have to pay out beginning Jan. 1 under the new 2.3 percent excise tax on all medical device sales as part of the landmark Patient Protection and Affordable Care Act, said Guy Childs, chief financial officer of Spectranetics. If the tax were levied this year, the company would pay between $3.07 million and $3.14 million, based on its revenue estimate for this year of between $133.5 million and $136.5 million.

“We aren’t going to cut back on product development or clinical research, but as we think about investing in the future we will probably think twice and be able to do less of it,” Childs told about 120 business and civic leaders attending a panel discussion during a lunch hosted by the Colorado BioScience Association and the Greater Colorado Springs Chamber and EDC at the Cheyenne Mountain Resort. “This tax is another variable that detracts from our ability to invest in innovation because it comes right off the top line of our revenue. It impedes further investment and makes it more difficult.”



Read more: http://www.gazette.com/articles/million-137679-tax-year.html#ixzz1uEEPkSc0 
Continue Reading

miRagen Therapeutics Announces the Publication of Compelling Data

Thursday, April 26, 2012

BOULDER, CO, April 26, 2012 – MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today that scientific results published in the journal Cell reveal the central role of the heart in whole-body metabolism.   

National Bioeconomy Blueprint

Thursday, April 26, 2012

Today, the Obama Administration announced its commitment to strengthening bioscience research as a major driver of American innovation and economic growth.  The National Bioeconomy Blueprint outlines steps that agencies will take to drive the bioeconomy—economic activity powered by research and innovation in the biosciences—and details ongoing efforts across the Federal government to realize this goal. 

Array BioPharma Names Ron Squarer CEO

Thursday, April 26, 2012

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced that Ron Squarer has been appointed Chief Executive Officer, effective immediately. Mr. Squarer has also been named to the Array Board of Directors.  

CBSA Seeks Region’s Top Start-up Companies for Venture Showcase

Tuesday, April 24, 2012

Colorado BioScience Association Seeks Region’s Top Start-up Companies for Venture Showcase Competition at BioWest 2012 

Accelr8 Attracts Up To $35 Million Private Equity Investment

Monday, April 23, 2012

DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (Amex: AXK) announced today that an investment group formed by Jack Schuler, John Patience, and Larry Mehren will invest a total of up to $35 million in Accelr8’s common stock. The purpose is to complete the product development and market introduction of Accelr8’s BACcel™ culture-free, diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.  

C2D2 Provides Grants for Drug Discovery Research

Monday, April 23, 2012

Awarding $216,282 to Colorado researchers in 2012. Including this year's awards, C2D2 has provided more than $660,000 to 11 drug discovery programs from all major research institutions in Colorado.  

April 2012 FOCUS Newsletter

Thursday, April 19, 2012

 

Mitomics names Burns Marketing as its agency

Thursday, April 19, 2012

LEADING DEVELOPER OF MOLECULAR-BASED TESTS FOR ONCOLOGY NAMES
BURNS MARKETING AS ITS AGENCY OF RECORD 

1 2 3 Next